Medicinova Stock Price, News & Analysis

MediciNova announced positive results from its Phase 2 clinical trial of MN-166 (ibudilast) in COVID-19 patients at risk for acute respiratory distress syndrome (ARDS). The trial showed significant improvements in key endpoints: 71% of patients in the MN-166 group were free of respiratory failure at Day 7 compared to 35% in the placebo group (p=0.02). Additionally, 65% of MN-166 patients were discharged by Day 7 versus 29% in the placebo group (p=0.02). The results suggest MN-166’s potential efficacy in treating ARDS, addressing a significant medical need amidst high mortality rates in affected patients.

MediciNova has announced that executives Yuichi Iwaki and Geoffrey O'Brien will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 1:00 p.m. ET. This discussion will focus on the development of MN-166 (ibudilast), a compound targeting neurological conditions, including ALS and progressive MS. MN-166 is in late-stage clinical trials for various neurodegenerative diseases and is also being assessed for acute respiratory distress syndrome (ARDS) risk.

MediciNova, Inc. (NASDAQ: MNOV) announced the publication of research demonstrating that MN-166 (ibudilast) prevents metastasis in a uveal melanoma (UM) model. The study, published in Molecular Cancer Research, revealed that MN-166 significantly reduced UM cell migration and metastasis in mice, emphasizing its potential as an adjuvant therapy for UM patients. The research identified macrophage migration inhibitory factor (MIF) as a key target, suggesting that MIF inhibition through MN-166 could address critical needs in metastatic cancer treatment.

MediciNova, a biopharmaceutical company traded as MNOV, announced the completion of patient enrollment in a Phase 2 clinical trial for MN-166 (ibudilast) targeting hospitalized COVID-19 patients at risk for acute respiratory distress syndrome (ARDS). The trial, which involved administering MN-166 or a placebo to subjects over 7 days, aims to assess its efficacy in preventing respiratory failure. Top-line results will be reported following data cleaning. MN-166 is also in late-stage development for other conditions like ALS and multiple sclerosis.

MediciNova, Inc. announced the FDA's completion of its review for a Phase 2 trial of MN-001 (tipelukast), aimed at treating non-alcoholic fatty liver disease (NAFLD), type 2 diabetes (T2DM), and hypertriglyceridemia. This trial follows promising results from a prior study where MN-001 successfully reduced serum triglycerides and improved lipid profiles, particularly in T2DM patients. The upcoming study will evaluate liver fat content and serum lipids, with full funding from MediciNova.

MediciNova has published a secondary analysis of a Phase 2 trial for MN-166 (ibudilast) in treating alcohol use disorder (AUD) in Alcoholism: Clinical and Experimental Research. The study involved 52 participants and revealed that MN-166 significantly reduced heavy drinking rates and cravings. The analysis showed it didn't alter stimulation/sedation levels but moderated daily stimulation effects on alcohol consumption. With an estimated 14.5 million people affected by AUD in the U.S., the study highlights a critical need for better treatment options.

MediciNova, a biopharmaceutical company traded as NASDAQ:MNOV, announced a Notice of Allowance from the Korean Intellectual Property Office for patents covering MN-001 (tipelukast) and its metabolite MN-002, aimed at treating advanced nonalcoholic steatohepatitis (NASH). The patent is expected to expire no earlier than May 2035 and covers multiple aspects of treatment, including dosing forms and frequencies. Positive results from a prior Phase 2 clinical trial of MN-001 with NASH patients alongside FDA's Fast Track designation further highlight its potential.

MediciNova, Inc. (NASDAQ: MNOV) has announced that Geoffrey O'Brien, the Vice President and Executive Officer, will present at the 2022 Virtual Growth Conference, scheduled for March 28-30, 2022. MediciNova is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its lead asset, MN-166 (ibudilast), is in Phase 3 trials for ALS and DCM, while MN-001 (tipelukast) is preparing for a Phase 2 trial in NASH. MediciNova has a strong pipeline with 11 programs currently in clinical development.

MediciNova, Inc. announced that MN-166 (ibudilast) is highlighted in the Global Spine Journal as a potential treatment for degenerative cervical myelopathy (DCM). The publication reviews therapies that support neuroprotection, neuroregeneration, and neuromodulation. MN-166 is noted for its anti-inflammatory and neuroprotective effects, making it the only drug currently in Phase 3 trials for DCM. Chief Medical Officer Kazuko Matsuda expressed optimism regarding MN-166's potential to aid patients with DCM, a condition that often leads to lifelong disability.